Explore our top-tier solutions engineered for cell therapy workflows, genomic research, and PCR analysis — designed for precision, scalability, and reproducibility.
Cell therapy represents one of the most transformative frontiers in modern medicine and life sciences. It involves the introduction, modification, or replacement of living cells into a patient to treat disease — ranging from CAR-T immunotherapy to stem cell transplantation and gene-edited cellular products.
Central to the development and quality control of these therapies is genomic analysis and PCR (Polymerase Chain Reaction) testing. These molecular techniques allow scientists to verify cell identity, confirm genetic modification, detect contamination, assess gene expression profiles, and ensure the safety and efficacy of therapeutic cell products before clinical use.
As regulatory requirements tighten globally and the pipeline of advanced therapy medicinal products (ATMPs) expands, the demand for high-quality cell culture consumables, cryopreservation tools, and molecular biology reagents has surged — making reliable laboratory supply partners more critical than ever.
PCR-based assays confirm successful gene editing, insertion, or knockout in therapeutic cell lines with high specificity.
Short tandem repeat (STR) profiling and qPCR panels authenticate cell lines and detect mycoplasma or viral contamination.
RT-PCR and digital PCR quantify therapeutic gene expression, surface marker mRNA, and potency biomarkers across cell batches.
The intersection of cell therapy and molecular diagnostics is one of the fastest-growing segments in global life sciences.
Understanding where the market is heading helps laboratories and manufacturers align their procurement and R&D strategies for long-term success.
CRISPR-Cas9 gene editing has revolutionized cell therapy manufacturing. Every edited cell batch requires rigorous on-target and off-target PCR screening — driving demand for ultra-sensitive PCR reagents, specialized plates, and cryogenic storage systems that preserve genomic fidelity post-editing.
Digital PCR is increasingly adopted in cell therapy QC to detect low-frequency genomic variants, insertional mutations, and residual disease markers. Microplate formats with precise well geometry — like 384-well plates — are critical for dPCR workflow throughput and accuracy.
As CAR-T and NK cell therapies move toward allogeneic "off-the-shelf" production, scalable cell factory systems and automated cryopreservation workflows become essential. Consistent cooling rates during freezing are directly linked to post-thaw viability and genomic stability.
Portable PCR platforms and miniaturized assay formats are enabling decentralized genomic testing closer to the patient. This trend requires compact, reliable consumables — including sealed microplates, cryotubes, and cell culture inserts — that maintain sample integrity across distributed lab networks.
Artificial intelligence platforms are being integrated with high-throughput PCR systems to analyze vast genomic datasets from cell therapy trials. This demands standardized, high-quality consumables that minimize variability and ensure data reproducibility across multi-site studies.
Regulatory agencies including FDA, EMA, and NMPA require stringent documentation for cell therapy manufacturing materials. GMP-compliant cryogenic tubes, cell culture dishes, and PCR plates with full traceability are now a prerequisite for IND and BLA submissions.
From early-stage discovery to clinical manufacturing, cell therapy and PCR genomic analysis intersect across every phase of the therapeutic development pipeline.
After viral transduction of T cells with chimeric antigen receptor (CAR) constructs, qPCR is used to quantify vector copy number per cell. This ensures consistent CAR expression levels, which directly correlate with therapeutic potency. High-quality PCR plates and cryogenic storage tubes are essential for sample integrity throughout this workflow.
During iPSC differentiation into target cell types (cardiomyocytes, neurons, hepatocytes), RT-PCR panels track lineage-specific marker genes in real time. Cell culture inserts with polycarbonate membranes support co-culture models that better mimic in vivo differentiation microenvironments for more physiologically relevant PCR data.
PCR-based mycoplasma testing is a mandatory quality control step in cell therapy manufacturing. Sensitive PCR assays performed on cell culture supernatants — collected from multi-well plates or cell factory systems — provide rapid, reliable contamination screening that protects both product integrity and patient safety.
Cryogenic tubes and controlled-rate freezing containers are the backbone of cell and genomic sample biobanking. Maintaining optimal cooling rates (typically -1°C/min) during cryopreservation preserves DNA integrity, RNA quality, and cell viability — all critical for downstream PCR analysis and longitudinal genomic studies.
CCK-8 cell viability assays in 384-well microplate formats enable rapid cytotoxicity profiling of candidate compounds. Positive hits are then validated using PCR-based apoptosis gene panels, creating a seamless phenotypic-to-genomic screening pipeline that accelerates drug discovery for cell therapy combination approaches.
For allogeneic cell therapy products, PCR-based HLA typing and STR profiling verify donor cell identity, confirm master cell bank authenticity, and support regulatory submissions. Scalable cell factory systems enable consistent expansion of donor-derived cells while maintaining genomic identity across manufacturing lots.
A streamlined, end-to-end process from cell sourcing to genomic validation — powered by Bioland™ consumables at every critical step.
Scalable cell factory systems support adherent cell culture expansion under GMP conditions.
CRISPR, viral vector, or mRNA-based gene delivery into target therapeutic cells.
qPCR / ddPCR verification of editing efficiency, copy number, and purity in microplates.
CCK-8 proliferation and cytotoxicity testing confirms cell health before cryopreservation.
Controlled-rate freezing containers and cryogenic tubes preserve genomic integrity long-term.
Bioland™ delivers a complete ecosystem of precision consumables that support every stage of the cell therapy and genomic analysis pipeline.
All Bioland™ products are manufactured under stringent quality management systems, with full lot traceability and documentation to support regulatory submissions for ATMPs.
From 384-well microplates with uniform well geometry to low-binding cryotubes that protect nucleic acid samples — every product is optimized to minimize variability in PCR-based genomic assays.
As a leading China-based manufacturer with global distribution, Bioland™ offers competitive pricing, consistent availability, and responsive technical support for laboratories worldwide.
From cell culture dishes and inserts to cryogenic storage, CCK-8 assay kits, and scalable factory systems — Bioland™ provides a single-source solution for integrated cell therapy workflows.
Bioland™ products are backed by rigorous internal validation and published application data, giving researchers confidence in reproducible results across genomic and PCR analysis platforms.
Bioland™ serves pharmaceutical companies, CROs, CDMOs, academic research institutes, and hospital laboratories across Asia, Europe, North America, and beyond.
Whether you're developing CAR-T therapies, conducting iPSC genomic studies, or scaling up cell manufacturing — Bioland™ provides the high-performance consumables and reagents your laboratory needs to succeed at every stage of the PCR and genomic analysis workflow.
Explore All Products →A comprehensive portfolio of cell culture consumables, cryopreservation solutions, and bioanalytical tools — all engineered for genomic and PCR analysis workflows in cell therapy research and manufacturing.
Trusted by leading pharmaceutical companies, CROs, CDMOs, academic institutions, and hospital research centers worldwide — our solutions power cell therapy genomic and PCR analysis workflows at every scale.